Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Upgrade Now
Frankfurt - Delayed Quote EUR

Oncopeptides AB (publ) (OND.F)

Compare
0.1544
+0.0014
+(0.92%)
At close: April 4 at 8:05:46 AM GMT+2
Currency in EUR All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
31,648
31,648
35,220
8,355
118,295
Cost of Revenue
2,663
2,663
-1,079
6
53,121
Gross Profit
28,985
28,985
36,299
8,349
65,174
Operating Expense
312,483
312,483
289,746
360,485
1,486,091
Operating Income
-283,498
-283,498
-253,447
-352,136
-1,420,917
Net Non Operating Interest Income Expense
-712
-712
5,000
1,733
-456
Pretax Income
-284,209
-284,209
-248,447
-337,680
-1,421,372
Tax Provision
398
398
664
271
8,946
Net Income Common Stockholders
-284,607
-284,607
-249,111
-337,951
-1,430,317
Diluted NI Available to Com Stockholders
-284,607
-284,607
-249,111
-337,951
-1,430,317
Basic EPS
-1.71
--
-2.76
-2.93
-13.54
Diluted EPS
-1.71
--
-2.76
-2.93
-13.54
Basic Average Shares
166,436.8420
--
90,257.6090
115,513.0390
105,651.2110
Diluted Average Shares
166,436.8420
--
90,257.6090
115,513.0390
105,651.2110
Total Operating Income as Reported
-283,498
-283,498
-253,447
-349,350
-1,420,917
Total Expenses
315,146
315,146
288,667
360,491
1,539,212
Net Income from Continuing & Discontinued Operation
-284,607
-284,607
-249,111
-337,951
-1,430,317
Normalized Income
-284,607
-284,607
-249,111
-337,951
-1,430,317
Interest Income
--
--
8,592
2,616
492
Interest Expense
528
--
5,785
883
948
Net Interest Income
-712
-712
5,000
1,733
-456
EBIT
-283,498
-283,498
-253,447
-336,797
-1,420,424
EBITDA
-283,498
-283,498
-253,447
-319,636
-1,405,430
Reconciled Cost of Revenue
2,663
2,663
-1,079
6
53,121
Reconciled Depreciation
4,540
--
11,040
17,161
14,994
Net Income from Continuing Operation Net Minority Interest
-284,607
-284,607
-249,111
-337,951
-1,430,317
Normalized EBITDA
-283,498
-283,498
-253,447
-319,636
-1,405,430
Tax Rate for Calcs
0.0002
0.0002
0.0002
0.0002
0.0002
12/31/2021 - 2/23/2017

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

APTA.ST Aptahem AB (publ)
1.4050
0.00%
 
ELIC.ST Elicera Therapeutics AB (publ)
2.9200
-1.02%
 
EGTX.ST Egetis Therapeutics AB (publ)
4.0250
-6.50%
 
BIOA-B.ST BioArctic AB (publ)
169.60
-3.36%
 
PHAR Pharming Group N.V.
7.69
+0.79%
 
BDRX Biodexa Pharmaceuticals Plc
1.6900
+14.97%
 
NKTR Nektar Therapeutics
0.5519
-8.09%
 
ZEAL.CO Zealand Pharma A/S
426.20
-7.99%